中文摘要：

目的探讨^18F-FDGPET／CT和3．0TMRI联合显像评分与Ki-67（一种增殖细胞核抗原）表达水平的相关性。方法18例经病理确诊的原发性乳腺癌患者术前行^18F—FDG PET／CT和3．0TMRI联合显像，对显像结果进行评分并与Ki-67的表达水平进行相关性分析。联合显像和术后病理标本的免疫组化检测在一周内完成。结果①乳腺癌最大标准化摄取值与Ki-67的表达水平呈正相关（r=0．473，P〈0．05）；②PET／CT和3．0TMRI联合显像评分与Ki-67的表达水平呈明显正相关（r=0．674，P〈0．01）。结论^18F—FDG PET／CT和3．OTMRI联合显像在乳腺癌的预后判断中可能具有重要的潜在价值。

英文摘要：

Objective To explore the correlation between combined imaging modalities of ^18F- FDG PET/CT and 3.0T MRI and expression of Ki-67 （proliferating cell nuclear antigen）in breast cancer. Methods A retrospective study was carried out in eighteen patients with pathologically confirmed pri- mary breast cancer, who underwent both ^18F-FDG PET/CT and 3.0T MRI examinations before operation. The interval between immunohistochemisty and combined imaging examinations was not more than one week after operation. The correlations between maximum standardized uptake value （SUVmax） as well as the score of combined imaging modalities and the expression level of Ki-67 were analyzed. Results ①A positive correlation between SUVmax and expression level of Ki-67 was demonstrated in breast cancer lesions（r=0.473, P〈0.05）. ②A significantly positive correlation between the score of combined imaging modalities and the expression level of Ki-67 was also noted（r=0.674, P〈0.01 ）. Conclusion Tumor proliferation can be reflected by the combined imaging modalities of ^18F-FDG PET/CT and 3.0T MRI, indicating a potential role in predicting prognosis of breast cancer.